Driessen, Julia http://orcid.org/0000-0001-9364-2501
Visser, Otto
Zijlstra, Josée M.
Lugtenburg, Pieternella J.
Plattel, Wouter J.
Kersten, Marie José
Dinmohamed, Avinash G. http://orcid.org/0000-0002-4767-6716
Funding for this research was provided by:
SHOW ('Stichting Hematologisch-Oncologisch Wetenschapsonderzoek') is a Dutch non-profit foundation that promotes scientific research in the field of hemato-oncology.
Article History
Received: 19 February 2020
Revised: 7 May 2020
Accepted: 13 May 2020
First Online: 28 May 2020
Compliance with ethical standards
:
: There is no financial support for this work that could have influenced the outcomes described in the manuscript. However, particular authors report a potential conflict of interest, which is described below. MJK: Millennium/Takeda: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Roche: Honoraria, Research Funding; Gilead: Honoraria; Kite Pharma: Honoraria; Novartis: Honoraria. PJL: Millennium/Takeda: Consultancy, Research Funding; Servier: Consultancy, Research Funding; Roche: Consultancy; BMS: Consultancy; Sandoz: Consultancy; Genmab: Consultancy. JMZ: Consultant/Advisor: Gilead, Roche, Takeda; Honoraria: Gilead, Roche, Takeda, Janssen. AGD: BMS: Research funding. All remaining authors have declared no competing financial interests.